Abstract Our aim was to use quantitative and qualitative analyses to gain further insight into the role of ceramide in cystic fibrosis (CF). Sphingolipid ceramide is a known inflammatory mediator, and its accumulation in inflamed lung has been reported in different types of emphysema, chronic obstructive pulmonary disease and CF. CF is caused by a mutation of the chloride channel and associated with hyperinflammation of the respiratory airways and high susceptibility to ongoing infections. We have previously demonstrated that de novo ceramide synthesis is enhanced in lung inflammation and sustains Pseudomonas aeruginosa pulmonary infection in a CF murine model. We used liquid chromatography and matrix-assisted laser desorption/ionization (MALDI) imaging coupled with mass spectrometry, confocal laser scan microscopy and histology analyses to reveal otherwise undecipherable information. We demonstrated that (i) upregulated ceramide synthesis in the alveoli is strictly related to alveolar infection and inflammation, (ii) alveolar ceramide (C16) can be specifically targeted by nanocarrier delivery of the ceramide synthesis inhibitor myriocin (Myr) and (iii) Myr is able to downmodulate pro-inflammatory lyso-PC, favouring an increase in anti-inflammatory PCs. We concluded that Myr modulates alveolar lipids milieu, reducing hyperinflammation and favouring anti-microbial effective response in CF mouse model.
Introduction
Sphingolipids are a large family of molecules which play structural and signalling roles (Aguilera-Romero et al. 2014) . Sphingolipid mediators have various involvements in human diseases (Brice and Cowart 2011; Hammad 2011; Airola and Hannun 2013; Maceyka and Spiegel 2014) . Recent findings highlight the role of ceramide among sphingolipids in the pulmonary demise typical of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) (Grassme et al. 2013; Petrache and Petrusca 2013) . Gulbins and coworkers demonstrated that ceramide accumulates in CF airways and that amytriptiline, an inhibitor of the ceramidereleasing enzyme acid sphingomyelinase, reduces lung inflammation and bacterial infection in mice and in patients (Teichgraber et al. 2008; Riethmuller et al. 2009 ). We recently demonstrated that de novo ceramide synthesis also sustains lung inflammation and infection in CF (Caretti et al. 2014) by using a murine CF model and pulmonary Pseudomonas aeruginosa infection to measure and pharmacologically target ceramide synthesis. Intratrachea injection of myriocin (Myr), the inhibitor of serine palmitoyl transferase (SPT), reduced Electronic supplementary material The online version of this article (doi:10.1007/s00210-017-1373-4) contains supplementary material, which is available to authorized users.
inflammation and bacterial infection in CF mice. Although significant, the overall ceramide increase upon infection in CF mouse lung was not as striking as expected. We suspected that, as previously suggested (Becker et al. 2010; Ulrich et al. 2010) , ceramide formation could be compartmentalized and that quantitation on whole lung homogenates could underrate changes that occur in limited areas, such as the alveolar compartment. A second major concern raised by our studies considered the disentangling of ambiguities in the cause-effect relationship linking ceramide to inflammation and infection. Specifically, it is still unclear whether ceramide increases in response to a general inflammatory setting or whether it is a key mediator that drives acute response into chronic inflammation and consequent chronic infection. Our aim was to prove that ceramide accumulation, inflammation, and bacterial colonization not only occur in the same lung region but also are strictly dependent on one another. We used different methods (liquid chromatography coupled with mass spectrometry (LC-MS), matrix-assisted laser desorption/ ionization (MALDI) imaging, immunomagnetic separation (IMS) and confocal laser scan microscopy (CLSM)) to analyse the precise topologies of ceramide accumulation, Pseudomonas aeruginosa and the inflammatory infiltrate, and we investigated the effect of ceramide synthesis inhibition in alveolar versus bronchial lung regions. We also explored the potential of solid lipid nanocarriers (SLNs) (Caretti et al. 2014) , for in situ delivery of Myr in diseased lungs. SLNs have a solid lipid core, show strong interaction with membranes and are a long-lasting drug release system. We wanted to evaluate their pulmonary dispersal and to compare the topography of drug action with those of ceramide accumulation, inflammation and consequent infection. Here, we describe how we combined multiple in vitro sphingolipid detection methods to cope with all of the above issues. Using LC-MS, we precisely quantified single ceramide species and their metabolic derivatives (sphingomyelins and cerebrosides) in the whole lung. Using IMS, we were able to map the abundance of precise ceramide species onto histological images from lung sections. Furthermore, as this analytical approach allows for the simultaneous detection of all molecules in a sample across a broad mass and hydrophobicity range, we correlated ceramide changes with overall metabolic changes in other anti-inflammatory lipids, such as phosphatidylcholine (PC) (Treede et al. 2007) , and pro-inflammatory lipids such as lyso-PC (Yoder et al. 2014) , within specific tissue areas. Lastly, through immunostaining and CLSM analyses, we confirmed the topography of ceramide within the lung and contrasted it with the location of bacterial infection. We concluded that the integrated use of these three different methodologies is able to reveal information that cannot be deciphered using just one single approach: (i) upregulated ceramide synthesis in the alveoli is strictly related to alveolar infection and inflammation; (ii) alveolar ceramide (C16) can be specifically targeted by SLN delivery of the ceramide synthesis inhibitor Myr; and (iii) Myr is able to downmodulate the same acyl chain bearing lyso-PC (C16 and C18) with a proinflammatory known action (Yoder et al. 2014) , favouring the increase in anti-inflammatory PCs.
Methods
Mice Twelve-week-old gut-corrected CFTR-deficient mice B6.129P2-Cftr tm1UNC TgN(FABPCFTR) (group KO) and congenic wild-type (Case Western Reserve University, Cleveland, OH, USA) (group WT) male and female mice were used. Mice were housed in filtered cages under specific pathogen conditions and permitted unlimited access to food and water. Myr administration was performed in the treated animal group, 24 h prior to infection. Once a deep stage of anaesthesia with 2,2,2,-tribromoethanol (Avertin, SigmaAldrich, USA) was reached, Myr loaded SLNs were intratrachea instilled by means of MicroSprayer® Aerosolizer-Model IA1C, attached to BFMJ-250 High Pressure Syringe^(Penn-Century Inc., USA). Control animals were treated with the corresponding empty SLNs. The total volume introduced in lungs was 50 μl, in mice of approximately 30 g each. This volume contained approximately 1.47 μg of compound/mouse in SLN-saline solution. Twenty four hours after treatment, animals (both KO and WT) were infected with 3-10 × 10 5 CFU of P. aeruginosa strain PAO1 planktonic cells, as previously described (Bragonzi 2010) . At 18 h post-infection, mice were euthanized and lungs were explanted. Part of the samples were homogenized in 1 ml of PBS containing protease inhibitors (Roche Italia, Italy) and homogenates divided in an aliquot for bacterial load counting (by serial dilution of homogenate sample in PBS and by plating on TSA) and an aliquot for lyophilization and lipid extraction for LC-MS analysis; part of the samples were embedded in a modified optimum cutting temperature (OCT) and prepared for immunohistochemistry or IMS (Berry et al. 2011) . The other aliquot was serially diluted 1:10 in PBS and plated onto TSA plates to determine lung bacterial load. All experiments were performed with a minimum of five animals per group and a minimum of two experiments for each kind of investigation method (two experiments for IMS, two experiments for LSCM, and four experiments for LCMS).
Myriocin-loaded solid lipid nanoparticles used for mice treatment Treatment of mice with Myr was achieved by using Myr-loaded SLNs (Nanovector srl, Italy) prepared as previously described. SLN loaded with drug was measured for Myr content, and a 1 mM Myr-SLN stock solution was prepared. This solution was diluted 1:12 in sterile saline, and 50 μl (1.47 μg of Myr and 8% SLN) was used for each mouse administration in the airways.
LC-MS analysis Sphingolipid extracts from both mice lungs and treated cells, fortified with internal standards (Ndodecanoylsphingosine, N-dodecanoylglucosylsphingosine, N-dodecanoylsphingosyl phosphorylcholine, C17-sphinganine (0.2 nmol each) and C17-sphinganine-1-phosphate (0.1 nmol), were prepared and analysed as reported.
Immunostaining and confocal microscopy analysis Frozen lungs were embedded in OCT (OCT-compound, Leica Instruments, Nussloch, Germany); serial 5-μm-thick sections were obtained in a cryomicrotome (Leica CM1510) and placed on silanized glass slides. The sections were dried for 3 min at room temperature, fixed in 4% buffered formalin for 45 min at 4°C, rinsed two times for 5 min in PBS, post-fixed with ethanol-acetic acid 2:1 (v/v) for 5 min at −20°C, rinsed twice for 5 min in PBS, boiled in 10 mM citrate buffer at pH 6.0 for 10 min, washed once in distilled water and three times in PBS and finally used for immunofluorescence. After treatment with 10% normal goat serum, the sections were incubated overnight at 4°C with a mouse anti-ceramide monoclonal antibody (Glycobiotech, Germany, diluted 1:100 in 1.5% normal goat serum) and a rabbit polyclonal anti-T7 directed against P. aeruginosa (kindly provided by Dr. Pier G.B, Institute of Medical Microbiology and Hygiene, University of Tubingen, Germany, 1:50), followed by 1-h incubation with goat antimouse IgM fluorescein or with goat anti-rabbit IgG Texas Red-conjugated secondary antibody, respectively (Alexa, diluted 1:1000 in PBS). Total nuclei were counterstained with the karyophilic dye Hoechst 33258 (300 ng/ml, Sigma) for 3 min at room temperature, in the dark, followed by rinsing twice in PBS. Sections on glass slide were then mounted in a 10:1 glycerol-PBS medium, pH 8.5, containing 0.1% p-phenylenediamine as anti-quenching agent. Confocal imaging was performed on a Leica SP2 confocal microscope (Leica Microsystems), using a ×40 (NA 1.25) oil immersion objective and 405, 488 and 633-nm lasers. Images were collected using sequential acquisition process in order to reduce spectral crosstalk between channels and stacks collapsed into projection images. Offline handling, segmentation and geometric density analysis were developed with LCS software (version 2.6.1; Leica Microsystems).
Histochemistry Both lungs from infected KO and WT mice, either pretreated with SLN-Myr or untreated (SLN-empty), were fixed in buffered formalin and routinely processed for histopathological evaluation. Briefly, lungs were sectioned and paraffin included. Twenty serial 3-μm-thick sections were cut at a microtome; slides at different levels (level 1, 11 and 20) were stained with haematoxylin and eosin to have a comprehensive estimation of the distribution of inflammatory infiltrate in all compartments. Slides were observed at a Leika light microscope. Image acquisition was performed by the NanoZoomer-XR C12000 series (Hamamatsu Photonics K.K., Tokyo, Japan). The site of inflammation (bronchial and bronchiolar compartment, intraparietal and endoluminal and alveoli) and its intensity (low: +, medium: ++ and high: +++) were considered. In each case, a median value of flogistic reaction on the three compartments was considered.
MALDI-IMS analysis
Lungs from infected CF and WT, either pretreated or not with SLN-Myr, were explanted 24 h after infection fixed, sliced at a thickness of 12 μm with a cryostat at 20°C and mounted onto a ITO glass, and DHB matrix was overlayed by sublimation onto the samples using a sublimation apparatus (ACE Glass) for 20 min at 50 mTorr pressure at 180°C. The MALDI-IMS analyses were performed by Ultraflex III time-of-flight mass spectrometer (Bruker Daltonics) with a SmartBeam laser operating at 200 Hz in positive linear mode using FlexControl 3.0 and FlexImaging 2.1 software packages (Bruker Daltonics). Ions were detected in the 480-900 m/z mass range with a sampling rate of 2 GS/s. The lateral resolution for MALDI-IMS was set to 50 μm, and a total of 100 laser shots were accumulated per pixel at constant laser power. Two-dimensional ion intensity maps and average spectra were created by FlexImaging 2.1 software (Bruker Daltonics).
In order to identify differentially expressed peaks, tandem mass spectrometry (MS/MS) analysis was performed using LIFT-TOF/TOF mode and the product ion characteristic head group of the lipid was used to classify the lipids of interest.
Statistical analyses Fluorescence quantitation and statistical evaluation. On the basis of the histological staining, regions of interest (ROIs) were defined in the tissue section using the FlexImaging 2.1 software (Bruker Daltonics); ROIs containing the same number of spectra (around 70) were created. Statistical analyses were carried out using the ClinProTools . Untreated KO or WT were considered as 100% of each ceramide specie (grey bars), and the percentages of ceramides were calculated in myriocin-treated lung homogenates. Data shows a significantly higher reduction of ceramides in KOtreated lung homogenate than in WT. ANOVA test was performed among all groups (p < 0.0001), followed by Bonferroni test in KO versus WT single-chain ceramides. ***p < 0.001 2.2 software (Bruker Daltonics), and during the preprocessing steps, the extracted mass spectra were internally recalibrated, normalized on their total ion and corrected by a baseline subtraction. An average spectrum created for each class was used for peak picking and to define integration ranges to be used to obtain the area of each peak (m/z species) in each single spectrum. A nonparametric Wilcoxon/ Kruskal-Wallis test was performed, with a significance cut-off point of p value <0.05. A receiver operator characteristic (ROC) analysis was performed to highlight peaks discriminating the compared classes (area under curve (AUC) >0.800). LC-MS and IMS, histochemistry image statistical evaluation. Most of the analyses, comparing treated and untreated, were performed by unpaired two-tailed Student's t test, p < 0.05. In some cases (reported in figure legend), ANOVA one-way test was performed, p < 0.05, followed by post-test Bonferroni.
Results
Ceramide levels correlate with P. aeruginosa lung colonies WT and CFTR KO mice were infected by intratracheal nebulization of 3 × 10 5 P. aeruginosa CFU. A group of mice received 50 μl containing a suspension of Myr-loaded SLN (1.47 μg/ mouse of the compound), 24 h prior to infection. Mice were sacrificed 24 h after infection, and lung was explanted for analyses. We measured total ceramide mass and P. aeruginosa lung colonies both in WT and KO-infected mice, either treated with Myr or untreated. We observed a strong direct correlation between lung ceramide content and total pulmonary bacterial colonies (statistical significance p = 0.0164), showing that ceramide accumulation is closely associated with infection ( Fig. 1) . This occurred both in WT and KO mice although as regards significant differences in absolute values, KO mice were more severely infected and showed higher ceramide levels than wild type (Caretti et al. 2014 ). Specific ceramide pools are increased in KO mice and modulated by myriocin The analyses of lung homogenate revealed similar ceramide species profiles both in WT and KO mice, although a few species are slightly but reproducibly higher in KO (mean value of total ceramide picomoles per milligramme of protein in WT mice 839.3 ± 61 versus KO mice 1058.2 ± 49, p = 0.038). Treatment with SLN-Myr reduced almost all ceramide species, both in WT and KO mice (Fig. 2a) . Specifically, higher significance in Myr-induced reduction was observed in the most representative ceramide species (Fig. 2a) (as C16 ceramide, mean ± SD: KO untreated 178 ± 16.9 versus treated 97.9 ± 10.2; saturated C24 ceramide, KO treated 217 ± 49.6 versus untreated 509.8 ± 4 9.2; monounsaturated C24:1-ceramide, KO treated 97.9 ± 10.2 versus untreated 178.6 ± 16.9). Although a minor species, C18 ceramide was significantly reduced by half (mean ± SD: KO treated 12.6 ± 1.5 versus untreated 23.8 ± 3.6). These observations suggest that KO mouse lung, upon infection, undergoes an increased synthesis of ceramide, mainly affecting C16 and C24 saturated/mono-unsaturated ceramides, compared to WT mouse lung. This is also supported by the previously reported increase of serine palmitoyl transferase expression in the same KO versus WT-infected mice (Caretti et al. 2014) . No significant variability was observed in the sphingomyelin pools (Fig. 2b) , whereas mono-glycosylated ceramides were affected by Myr treatment, with the C16 and C18 acyl chain species being significantly reduced in KO treated versus untreated lungs (Fig. 2c) . When considering the percentage change in ceramides in the KO and WT mice, it is interesting to note that the Myr-induced reduction in the percentage of C16, C18 and C24 ceramides is significantly higher in KO than in WT mice (Fig. 2d) , indicating that de novo ceramide synthesis is enhanced and drug treatment is effective in CF murine model lung.
Inflammatory lyso-PC is reduced by myriocin in infected mice PC is a known anti-inflammatory lipid, and oral phosphatidylcholine alleviates inflammatory activity caused by ulcerative colitis (Stremmel et al. 2005) . Lyso-PC is obtained through the action of cPLA2 on PC and exerts proinflammatory actions. Choline is shared among sphingolipids and glycerophospholipids, being incorporated into SM and PC, and ceramide is able to activate cPLA2 (Sato et al. 2009; Kitatani et al. 2004; Huwiler et al. 2001 ). We observed a slight but consistent increase in PC, with a particularly high mass in cells and tissue, and a significant drop in lyso-PC (mean value of lyso-PC picomoles per milligramme of protein ± SD: value 5167 ± 99 versus 4393 ± 200) in infected and myriocin-treated KO mice versus infected and untreated mice (Fig. 3a, b) . Since PC mass is particularly high in tissue and cells, a slight increase must be taken into account. PC can be metabolized in different by-products, so lyso-PC basal levels are normally much lower, and its increase along with an increase in ceramide synthesis indicates that, in KO mice, it is able to modulate glycerophospholipid pools and promote the formation of pro-inflammatory lyso-PC.
Localization of ceramide and P. aeruginosa within the lungs In order to understand the meaning of ceramide increase, we investigated the topology of its accumulation within the lung and co-related it to P. aeruginosa localization using confocal laser scanning microscopy. Twenty-four hours after infection or Myr treatment and infection, the lungs of KO and WT mice were explanted and stained with anti-ceramide antibodies and with anti-P. aeruginosa antibodies. Myr treatment succeeded in reducing both ceramide and P. aeruginosa PAO1 strain in the alveolar and bronchial regions (Fig. 4a, b) . DAPI-positive cells only, provided us with confirmation of LC-MS data and allowed us to discriminate between alveolar and bronchial ceramides. We measured an increased ceramide signal in infected KO versus WT lungs and a slight but significant increase in P. aeruginosa infection in KO lungs (Fig. 4c ), in agreement with the LC-MS quantitation of ceramides and the CFU count of Fig. 1 . We also found a higher accumulation of ceramide in the alveolar areas (Fig. 4a , infected only WT panel a and KO infected only panel g), an overlap of P. aeruginosa in the alveolar regions Ceramide and immune infiltrate located in the alveolar areas In our previous publication, we demonstrated that Myr is able to reduce the transcription of inflammatory mediators by evaluating the whole lung homogenate of KO and WT mice (Caretti et al. 2014 ), although we were unable to obtain significant differences in the inflammatory cells present in BAL of treated and untreated mice. In order to clarify the role of Myr in the acute immune response, we used light microscopy to evaluate the presence of infiltrate in infected KO and WT mice, either treated with Myr or untreated. We noticed a basal difference between infected KO and WT mice, with the former exhibiting a higher and more widespread infiltrate, especially in the lower airways (bronchioli and alveoli, Fig. 5a-c, g-i) . We observed a dramatic reduction of inflammatory cells in Myr-treated lungs (Fig. 5 WT mice d-f and KO mice l-n), which was particularly evident in the KO alveolar areas (n). In treated mice, flogosis showed a Bpatchyp attern, with almost healthy areas near unhealthy zones, where groups of neutrophils and, to a lesser extent, macrophages were commonly detected. In untreated mice, the same inflammatory reaction involved all the compartments studied equally. The results are summarized in Table 1 . These observations confirm that localized control of sphingolipid metabolism, obtained through alveolar Myr delivery, is highly effective in lung infection and inflammation. We concluded that SLN drug delivery is highly suitable for alveolar targeting.
Quantification and topology in vivo of single ceramide species In order to confirm the localization of ceramide and to obtain its quantitative fluctuation within tissue, we performed a MALDI imaging analysis. Lungs from infected CF and WT mice, some of which pretreated with SLN-Myr, were explanted 24 h after infection. They were then fixed, sliced and embedded into matrix for MALDI-TOF analysis. Utilizing haematoxylin and eosin-stained images, ROIs of lung sections were defined in each MALDI-IMS experiment and peak areas within the 480-900 m/z range were then submitted to statistical analysis. Slices were also scanned and stained for histochemistry, and the images were overlapped. As far as ceramide species were concerned, a 538.20 m/z peak, corresponding to C16 ceramide, was detected in all samples, and the peak level was reduced using SLN-Myr treatment in both WT and KO mice, in accordance with UPLC-TOF data (Fig. 6a) . Moreover, the extracted ion MALDI image of the 538.20 m/z peak indicates a relatively even intensity within the lung parenchyma (Fig. 6b) , while SLN-Myr treatment reduces C16 ceramide in the alveolar region more than in the bronchial region, both in WT and KO mice (Fig. 6a versus c) .
To better characterize sphingolipid differences related to treatment in WT and KO mice and find other species capable of discriminating these groups, a statistical analysis of spectra obtained through MALDI-IMS experiments was performed using ClinProTools software. In particular, a ROC analysis was performed to highlight discriminating peaks (AUC > 0.800). By comparing WT Myr untreated versus treated, we found 30 differentially expressed peaks (12 increased and 18 decreased after pharmacological treatment) with p < 0.5 and CV < 20% (Table 1) , 9 of which were identified by MALDI-LIFT-MS/MS analysis directly on tissue slices ( Supplementary Figs. 1-10 ). The whole analysed slice is reported in Fig. 7a . The positive ion collision-induced dissociation (CID) analysis of m/z 496.42 and 524.52 peaks identified C16 and C18 lyso-PC, respectively (Fig. 7b, c) . As found for C16-Cer, these ions had lower intensities in treated samples than in those that were not treated and were evenly distributed in the lung slice (Fig. 7b, c) . On the other hand, peaks at m/z 732. 78, 754.72, 780.67, 782.68, 804.58 and 806.59 , corresponding to 32:1-PC (M + 1), 32:1-PC (M + Na), 34:2-PC (M + Na), 34:1-PC (M + Na), 36:4-PC (M + Na) and 38:6-PC (M + 1), respectively, were higher in treated samples. In addition, 32:1-PC (M + 1), 32:1-PC (M + Na) and 34:1-PC (M + Na) showed a distribution very similar to C16-Cer and lyso-PC species (Fig. 7d, e, g ), whereas the signal corresponding to 34:2-PC (M + Na) was evenly distributed across the lung slice with a slight increment in the bronchus region (Fig. 7f) . By contrast, MALDI analysis of 36:4-PC (M + Na) and 38:6-PC (M + 1) indicated that these phospholipid molecular ions were highly abundant along the bronchus and were also present in the alveolar region (Fig. 7h, i) . Regarding the comparison between untreated versus treated KO mice, 14 differentially expressed peaks (7 increased and 7 decreased after pharmacological treatment) with p < 0.5 and CV < 20% were detected (Tables 2 and 3) , and 5 of them were identified by MALDI-LIFT-MSMS analysis ( Supplementary  Fig. 1 ). In particular, peaks at m/z 732. 78, 754.72, 760.78, 770.69 and 780.78 , corresponding to 32:1-PC (M + 1), 32:1-PC (M + Na), 34:1-PC (M + 1), 32:1-PC (M + K) and 34:2-PC (M + Na), respectively, were augmented in treated samples.
Identified phosphatidylcholines showed even distribution along the tissue slice with the exception of 34:2-PC, which was only slightly expressed in the bronchus (Fig. 8) . Overall, data obtained using IMS demonstrate that (i) C16 ceramide is more abundant in alveolar areas and (ii) C16 ceramide and lyso-PCs, the latter being known pro-inflammatory mediators, are reduced with Myr treatment, favouring an increase in PC (see hypothesis scheme, Fig. 9 ).
Discussion
The study of sphingolipid mediators is quite challenging due to the large number of bioactive molecules metabolically converting one into another, their different signalling in relation to subcellular distribution or extracellular release, their subtle switches from homeostatic concentration to accumulation and related Balarm-stress^signals and, last but not least, their diverse level of hydrophobicity, requiring appropriate extraction from samples. This document aims to embrace different analytical techniques and integrate all the data obtained, in order to achieve conclusions that cannot be fully deduced from a single analysis. After decades of sphingolipid evaluation using labelled precursors, in vitro or in vivo, the arrival of LC-MS analysis for lipidomic studies allows accurate quantitation and, moreover, the distinction among all different species. The evaluation of single-species fluctuations has opened up the possibility to define actions and metabolic routes for previously underestimated molecules such as C18 versus C16 ceramide (Karahatay et al. 2007) , dihydroceramides versus ceramides (Fabrias et al. 2012) , as well as sphingosine-1-phosphate versus sphingosines (Takabe et al. 2008) and (Fabelo et al. 2011; Fiedorowicz et al. 2014; Panchal et al. 2014) or in lung infection and inflammation (Ulrich et al. 2010) . Research requires the identification of the location of sphingolipid action both for the evaluation of their role and in order to approach pharmacological targeting. Immunocytochemical studies have been applied for the location of ceramides within tissue. In 1992, an interesting article by Hannun's group was published in JLR, assessing and questioning the specificity and the reliability of different ceramide antibodies (Cowart et al. 2002) . Being mostly membrane embedded, it is quite difficult to detect the specific binding of ceramide antibody, although several authors reported successful use of this tool. IMS, an innovative recent application of MALDI imaging to MS, can trace lipid One of our main unanswered questions was Bhow is ceramide accumulation related to lung infection?.^On one hand, ceramide deriving from increased plasma membrane sphingomyelinase activity, previously demonstrated by other authors (Riethmuller et al. 2009 ), can be a consequence of the engagement of pattern recognition or inflammatory mediator receptors, within the context of a self-resolving inflammatory response triggered by acute bacterial infection. On the other, the increase of the rate-limiting enzyme of de novo sphingolipid synthesis, recently reported by us and by others in lung inflammation (Petrache and Petrusca 2013; Caretti et al. 2014) , is probably due to a metabolic switch of the airways' epithelia, which is partially responsible for the chronic inflammation that characterizes CF-diseased lung and encourages infection rather than opposing it. In our CF mice model, we observed an antiinflammatory effect of Myr associated to a decrease in bacteria lung colonization. We demonstrated that Myr was more effective in KO than WT mice (Fig. 2d) . We concluded that ceramide increase is particularly enhanced in KO mice, via its de novo synthesis, and Myr is specifically effective in counteracting sphingolipid-altered metabolism in CF. In support of this idea, thanks to precise quantitation offered by LC-MS and with the broad insight offered by IMS, we found that other pro-inflammatory lipids are upregulated at the same time as ceramide, suggesting a comprehensive lipid dysmetabolic reaction to infection. It is important to note that the pharmacological inhibition of ceramide synthesis is able to regulate other inflammatory lipids, by reducing known inflammatory lyso-PC production (Yoder et al. 2014) and increasing the accumulation of anti-inflammatory PC (Treede et al. 2007 ). Lyso-PC derives from phospolipase activity, and it was previously reported that ceramide is able to activate cytosolic PLA2 (Sato et al. 2009; Kitatani et al. 2004; Huwiler et al. 2001) , possibly creating a metabolic loop between the two inflammatory molecules. It is interesting to note that species containing saturated C16 (and C18) acyl chains, previously reported to have specific inflammatory activity (Yoder et al. 2014) , are significantly reduced both in ceramides and lyso-PC families, suggesting that Myr treatment may control palmitate availability for other metabolic reactions, such as the formation of anti-inflammatory PC, thanks to the downmodulation of stress-induced ceramide synthesis. These data highlight a central role for ceramide metabolism in the metabolism of inflammatory lipids and suggest that the rate of de novo sphingolipid synthesis is carefully balanced and plays a sentinel role in the response to stress and in the switch to a pathological state. This is an important concept that requires exploration in other chronic inflammatory settings with the aim of being considered as a therapeutic target. Moreover, our data confirm the idea that bacterial infection from the upper airways reaches the inner lungs and that there is a significant burden of alveolar epithelia favoured by local ceramide accumulation and consequent recruitment of inflammatory cells. The demonstrated phenotype switch in the infectious population and the acquisition of resistance mechanisms (Bragonzi et al. 2009 ) can be associated with bacterial flow from the upper to lower airways and, lastly, the alveoli (McAdam et al. 2011) . It is mandatory to approach drug delivery methods that ensure the targeting of the alveolar region. Myr treatment evidenced an overall reduced inflammation with pro-resolving patchy granulocyte aggregates and no inflammation-related extensive damage of the alveolar structure. Our solid lipid nanoparticles demonstrated a marked ability to reach the alveolar compartment and to efficaciously release the drug.
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